HIV prevention jab offers hope in Uganda but doses are hard to find

A new injectable HIV prevention drug is showing promise in Uganda, offering a potential lifeline to those at risk of contracting the virus. The drug, lenacapavir, has been shown to be highly effective in preventing HIV infection, but its availability is severely limited, making it difficult for those who need it most to access treatment. This shortage is a major concern, as it could hinder the drug's potential to make a significant impact on the country's HIV epidemic.

Why it matters

An injectable HIV drug is in short supply in Uganda, which may lead to a significant impact on public health and the country's efforts to combat the disease. The shortage may also affect the country's economic growth and development.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to Africanews. For information only — not financial advice.